FDA Clearance Tracker · P170043
iStent inject Trabecular Micro-Bypass System (Model G2-M-IS)
Last checked: Nov 19, 2026Latest source record: Jun 21, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Jun 21, 2018
Approved
Time to decision
182 days
Received Dec 21, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P170043
- Device name
- iStent inject Trabecular Micro-Bypass System (Model G2-M-IS)
- Applicant
- Glaukos Corporation
- Applicant location
- San Clemente, CA
- Received
- Dec 21, 2017
- Decided
- Jun 21, 2018
- Decision
- Approved
- Supplements
- 19 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Intraocular pressure lowering implant (OGO)
- Device class
- Class III
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for the iStent inject® Trabecular Micro-Bypass System (Model G2-M-IS). This device is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code OGO. The earliest in FDA's data is P000026, decided Jul 12, 2001.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Glaukos Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K220032 · Decided Aug 2, 2022 · 209 days after receipt
Device type: Implant, Eye Valve (KYF) · Ophthalmology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.